NASDAQ:CHRS Coherus Oncology (CHRS) Stock Price, News & Analysis $0.53 0.00 (0.00%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$0.52 0.00 (-0.67%) As of 11/13/2026 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Coherus Oncology Stock (NASDAQ:CHRS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Coherus Oncology alerts:Sign Up Key Stats Today's Range$0.50▼$0.5450-Day Range$0.53▼$1.4352-Week Range$0.50▼$2.62Volume4.31 million shsAverage Volume2.35 million shsMarket Capitalization$81.19 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingModerate Buy Company Overview Coherus Oncology, formerly Coherus BioSciences, is a biopharmaceutical company focused on developing and commercializing cancer treatments. Its portfolio includes LOQTORZI (toripalimab-tpzi), an immune checkpoint inhibitor that targets PD-1 and is approved in the United States for certain patients with nasopharyngeal cancer. The company is also advancing a pipeline of investigational immuno-oncology medicines. Coherus historically built its business around biosimilar medicines before shifting its focus to oncology. Coherus is headquartered in the United States and holds U.S. commercial rights to LOQTORZI. The drug was developed by China-based Junshi Biosciences, which partnered with Coherus for its commercialization in the United States.AI Generated. May Contain Errors. Read More Coherus Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreCHRS MarketRank™: 1.69352708058 of 5 starsCoherus Oncology scored higher than 34% of companies evaluated by MarketBeat, and ranked 737th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingCoherus Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCoherus Oncology has a consensus price target of $11.00, representing about 1,993.2% upside from its current price of $0.53.Amount of Analyst CoverageCoherus Oncology has only been the subject of 2 research reports in the past 90 days.Read more about Coherus Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Coherus Oncology are expected to remain at ($0.83) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coherus Oncology is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coherus Oncology is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoherus Oncology has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.87% of the float of Coherus Oncology has been sold short.Short Interest Ratio / Days to CoverCoherus Oncology has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Coherus Oncology has recently increased by 2.09%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCoherus Oncology does not currently pay a dividend.Dividend GrowthCoherus Oncology does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.11 News SentimentCoherus Oncology has a news sentiment score of -0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Coherus Oncology this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for CHRS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows3 people have added Coherus Oncology to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Coherus Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders7.22% of the stock of Coherus Oncology is held by insiders.Percentage Held by Institutions72.82% of the stock of Coherus Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Coherus Oncology's insider trading history. Receive CHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coherus Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CHRS Stock News HeadlinesCoherus Oncology (NASDAQ:CHRS) Stock Rating Lowered by Wall Street ZenNovember 14 at 1:43 AM | americanbankingnews.comOncolytics Biotech Announces Clinical Supply Agreement With Coherus to Evaluate Pelareorep and Toripalimab in SCAC StudyNovember 13 at 12:50 PM | quiverquant.comQYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today. | Profits Run (Ad)Coherus Oncology to lay off 30% of staff as it zeroes in on a rare, aggressive cancerNovember 10, 2026 | bizjournals.comCoherus Q3 Net Loss Narrows; Sharpens Focus On Tagmokitug, LOQTORZI GrowthNovember 10, 2026 | rttnews.comCoherus Oncology (CHRS) Q3 2026 Earnings Call TranscriptNovember 10, 2026 | finance.yahoo.comCoherus Oncology: 3 Key Takeaways for Long-Term InvestorsNovember 10, 2026 | fool.comCoherus Oncology, Inc. (CHRS) Q3 2026 Earnings Call TranscriptNovember 9, 2026 | seekingalpha.comSee More Headlines CHRS Stock Analysis - Frequently Asked Questions How have CHRS shares performed this year? Coherus Oncology's stock was trading at $1.42 on January 1st, 2026. Since then, CHRS stock has decreased by 63.0% and is now trading at $0.5255. How were Coherus Oncology's earnings last quarter? Coherus Oncology, Inc. (NASDAQ:CHRS) posted its earnings results on Monday, November, 9th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.03. The biotechnology company had revenue of $14.27 million for the quarter, compared to analyst estimates of $15.90 million. Coherus Oncology had a negative trailing twelve-month return on equity of 274.46% and a negative net margin of 253.43%. Read the conference call transcript. Does Coherus Oncology have any subsidiaries? Coherus Oncology subsidiaries include InteKrin, Coherus Intermediate Corp, InteKrin Russia, and InteKrin Therapeutics Inc.. When did Coherus Oncology IPO? Coherus Oncology (CHRS) raised $85 million in an initial public offering (IPO) on Thursday, November 6th 2014. The company issued 6,296,300 shares at a price of $12.00-$15.00 per share. Who are Coherus Oncology's major shareholders? Top institutional shareholders of Coherus Oncology include State Street Corp (1.57%), Empowered Funds LLC (0.11%), Tyche Wealth Partners LLC (0.09%) and Ieq Capital LLC (0.02%). Insiders that own company stock include Dennis M Lanfear and Mats Wahlstrom. View institutional ownership trends. How do I buy shares of Coherus Oncology? Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Coherus Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Coherus Oncology investors own include NVIDIA (NVDA), Exelixis (EXEL), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), TG Therapeutics (TGTX), CRISPR Therapeutics (CRSP) and Intel (INTC). Company Calendar Last Earnings11/09/2026Today11/15/2026Jefferies Global Healthcare Conference11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, CHRS's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CHRS CIK1512762 Webwww.coherus.com Phone(650) 649-3530FaxN/AEmployees144Year Founded2010Price Target and Rating Average Price Target for Coherus Oncology$11.00 High Price Target$12.00 Low Price Target$10.00 Potential Upside/Downside+1,993.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$168.02 million Net Margins-253.43% Pretax Margin-289.91% Return on Equity-274.46% Return on Assets-69.87% Debt Debt-to-Equity Ratio2.08 Current Ratio1.51 Quick Ratio1.45 Sales & Book Value Annual Sales$42.17 million Price / Sales1.93 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book1.05Miscellaneous Outstanding Shares154,500,000Free Float143,346,000Market Cap$81.19 million OptionableOptionable Beta1.03 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:CHRS) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredReport: OCC clears Trump-linked bankI told investors that a Trump-backed crypto bank could be approved any day. On August 14, it was. Federal r...Crypto 101 Media | SponsoredGlobal Industrial Powerhouse Taps Nasdaq Drone MicrocapA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.